Phosphodiesterase (PDE) III is an enzyme in vascular smooth muscle that metabolizes cyclic adenosine monophosphate (cAMP). Milrinone inhibits PDE III, increasing the availability of cAMP. Cyclic guanosine monophosphate (cGMP), which is regulated by nitric oxide (NO), also inhibits PDE III. The endothelial NO component of prostacyclin (PGI2)-mediated vasodilation is reduced in aging. This study investigated if PGI2-mediated vasodilation during concomitant inhibition of endothelial NO and smooth muscle PDE III is affected by healthy aging. PDE III was inhibited with milrinone in 10 older subjects and 10 young matched controls while simultaneously infusing NG-monomethyl-l-arginine acetate (l-NMMA) to remove the confounding inhibitory effects of cGMP on PDE III. Incremental doses of PGI2 and sodium nitroprusside (SNP) were administered to the brachial artery during separate trials. l-NMMA decreased baseline blood flow similarly, and the addition of milrinone increased baseline blood flow similarly in both groups. The forearm blood flow responses to PGI2 were similar between groups (younger: 7.62 ± 0.72; older: 6.88 ± 0.81 mL•dL-1 FAV•min-1 at the highest dose of PGI2). SNP responses were also similar. This study suggests that the vasodilator pathway associated with PDE III function, the bioavailability of cAMP, and the interaction with cGMP may be preserved in healthy aging.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)